Alfacon600 mg

Alfacon 600 mg are indicated for the management of chronic kidney disease (CKD) to help reduce complications associated with impaired protein metabolism.

They are commonly used for:

• Prevention and treatment of protein malnutrition in patients with CKD on a low-protein diet (≤40 g/day)
• Delaying progression of renal failure in patients with reduced kidney function
• Reducing uremic symptoms and nitrogenous waste accumulation
• Nutritional support in advanced CKD, especially when glomerular filtration rate (GFR) is <25 mL/min
• Improving metabolic balance and maintaining essential amino acid supply without increasing nitrogen load

This combination supports better nutritional status while minimizing the burden on compromised kidney function.

Alfacon 600 mg tablets contain a balanced combination of essential amino acids and their ketoanalogues, formulated to support protein metabolism in patients with chronic kidney disease (CKD) while minimizing nitrogen load.

Each film-coated tablet contains:

• Calcium-3-methyl-2-oxo-valerate (α-ketoanalogue of isoleucine) – 67 mg
• Calcium-4-methyl-2-oxo-valerate (α-ketoanalogue of leucine) – 101 mg
• Calcium-2-oxo-3-phenylpropionate (α-ketoanalogue of phenylalanine) – 68 mg
• Calcium-3-methyl-2-oxobutyrate (α-ketoanalogue of valine) – 86 mg
• Calcium-DL-2-hydroxy-4-(methylthio) butyrate (methionine analogue) – 59 mg
• L-lysine acetate USP (equivalent to lysine 75 mg) – 105 mg
• L-threonine USP – 53 mg
• L-tryptophan USP – 23 mg
• L-histidine USP (as histidine hydrochloride monohydrate) – 38 mg
• L-tyrosine USP – 30 mg

This formulation provides essential amino acids while reducing urea formation, helping maintain nutritional balance in CKD patients on protein-restricted diets.

Alfacon 600 mg are nitrogen-free precursors of essential amino acids designed to support protein metabolism in patients with chronic kidney disease (CKD) while reducing nitrogen burden.

These compounds follow similar metabolic pathways as amino acids but undergo transamination, where keto- and hydroxy-analogues are converted into their corresponding essential amino acids by utilizing nitrogen from non-essential amino acids. This process helps recycle amino groups and significantly reduce urea formation.

By providing essential amino acid support with minimal nitrogen intake, this combination:

• Improves protein metabolism and nutritional status
• Reduces accumulation of uremic toxins
• Helps maintain nitrogen balance in low-protein diets
• Supports renal function preservation

Alfacon 600 mg may interact with certain medications, particularly those affecting calcium balance and drug absorption.

With medicines:

• Calcium-containing products: May increase the risk of hypercalcemia; monitoring of serum calcium levels is recommended.
• Aluminum hydroxide: May require dose adjustment and monitoring of serum phosphate levels.
• Cardioactive glycosides (e.g., digoxin): Increased risk of cardiac arrhythmias due to elevated calcium levels.
• Drugs forming complexes with calcium: Includes tetracyclines, quinolones (e.g., ciprofloxacin, norfloxacin), iron, fluoride, and estramustine—may reduce absorption of these drugs.

Administration advice:

• Maintain at least a 2-hour interval between Alfacon 600 mg and interacting medications to avoid reduced efficacy.

Alfacon 600 mg are generally well tolerated, with a low incidence of adverse effects when used as prescribed in chronic kidney disease.

Possible side effects include:

• Hypercalcemia (very rare): Elevated calcium levels may occur in susceptible patients
• Metabolic imbalance (indirect): Usually related to excessive calcium intake or vitamin D supplementation

Management of side effects:
If hypercalcemia occurs, reduction of vitamin D intake and other calcium sources is recommended. In persistent cases, dose adjustment or discontinuation of Alfacon 600 mg may be necessary under medical supervision.

Alfacon 600 mg should be used during pregnancy and lactation only with caution due to limited clinical data in humans.

Pregnancy:
There are no adequate and well-controlled studies in pregnant women. However, animal studies have not shown direct or indirect harmful effects on pregnancy, fetal development, parturition, or postnatal development. Therefore, use during pregnancy should be considered only when clearly necessary and under strict medical supervision.

Lactation (Breastfeeding):
There is no available clinical experience regarding the use of Alfacon 600 mg during breastfeeding. Caution is advised, and use should be based on a careful risk–benefit assessment by a healthcare professional.

General advice:
Alfacon 600 mg should be prescribed during pregnancy and lactation only when the expected therapeutic benefit outweighs potential risks.

Alfacon 600 mg should be used with careful monitoring to ensure safe and effective therapy in patients with chronic kidney disease.

Key precautions include:

• Serum calcium monitoring: Regular monitoring of serum calcium levels is required to prevent hypercalcemia.
• Adequate calorie intake: Patients should maintain sufficient caloric intake to ensure proper utilization of amino acid supplementation.
• Phenylketonuria (PKU): Use with caution in patients with hereditary phenylketonuria, as the formulation contains phenylalanine.
• Serum phosphate monitoring: Required when used with aluminium hydroxide, due to potential effects on phosphate balance.

General warning:
Close biochemical monitoring is essential during therapy to maintain metabolic balance and prevent complications related to calcium, phosphate, and amino acid metabolism.

Store at a temperature not exceeding 30°C in a dry place. Protect from light & moisture.